Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXT3003 in Charcot-Marie-Tooth Type 1A
NCT05092841Phase 3Completed
- Sponsor
- GeneNet Co, Ltd
- Start
- Sep 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of PXT 3003 in Charcot-Marie-Tooth disease type 1A (CMT1A), sponsored by GeneNet Co, Ltd. Started Sep 2021; status: completed.
02
Drugs
PXT 3003
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on NCT05092841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092841.